Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David Vaux

Molecular pathology of post-translational modification

The group is interested in the molecular mechanisms by which pathological perturbations in the post-translational modifications of proteins (including proteolytic maturation, oligomeric assembly, ubiquitination, phosphorylation and fatty acyl modification) can lead to severe human disease. Conditions resulting from defective or altered post-translational modification are extremely diverse, ranging from Alzheimer’s disease, Type II diabetes, neural tube defects, lipodystrophy and cardiomyopathy, to tumour metastasis and premature ageing syndromes.